Silo Pharma, Inc. (SILO)
- Previous Close
1.7500 - Open
1.6800 - Bid --
- Ask --
- Day's Range
1.6800 - 1.7700 - 52 Week Range
1.2160 - 3.0500 - Volume
3,656 - Avg. Volume
203,765 - Market Cap (intraday)
5.033M - Beta (5Y Monthly) 1.34
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1800 - Earnings Date May 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Silo Pharma. Inc., a developmental stage biopharmaceutical company, develops traditional therapeutics and psychedelic medicine. Its lead program includes SPC-15, an intranasal drug targeting post-traumatic stress disorder (PTSD) and stress-induced anxiety disorders; and SP-26, a ketamine-based loaded implant indicated for fibromyalgia and chronic pain relief. The company's preclinical products include SPC-14 to treat Alzheimer's disease; and SPU-16, a central nervous system homing peptide targeting the central nervous system with indication in multiple sclerosis. It also seeks to acquire and/or develop intellectual property or technology rights from universities and researchers to treat rare diseases, including the use of psychedelic drugs, such as psilocybin and ketamine, as well as depression, mental health issues, and neurological disorders. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.
silopharma.comRecent News: SILO
Performance Overview: SILO
Trailing total returns as of 5/13/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SILO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SILO
Valuation Measures
Market Cap
4.78M
Enterprise Value
-2.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
71.76
Price/Book (mrq)
0.77
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.86%
Return on Equity (ttm)
-43.97%
Revenue (ttm)
72.1k
Net Income Avi to Common (ttm)
-3.63M
Diluted EPS (ttm)
-1.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
7.67M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.78M
Research Analysis: SILO
Company Insights: SILO
SILO does not have Company Insights